Ocrelizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ocrelizumab and local guidelines before prescribing.
Anti-CD20 monoclonal antibody
Mechanism
Anti-CD20 monoclonal antibody.
Uses
Relapsing and primary progressive multiple sclerosis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infusion reactions, infections, hypogammaglobulinaemia, malignancy risk.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active infection, malignancy
Monitoring
Immunoglobulins, infection signs
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Hepatitis B screening before starting; vaccinate beforehand.
More from the textbook: uses, cautions and other points
- Ocrelizumab , ofatumumab , ublituximab | Anti-CD20 antibodies (B-cell depletion) | Infusion or injection reactions, infections, hepatitis B reactivation (screen), low immunoglobulins; ocrelizumab also for early primary progressive MS
Neurology: Anatomy, Physiology and Pharmacology - Ocrelizumab / ofatumumab | Anti-CD20; high efficacy; PPMS (ocrelizumab); HBV screening, infections, poor vaccine response.
Neurology: Multiple Sclerosis and inflammatory disease - Natalizumab / ocrelizumab / alemtuzumab | MS DMTs; PML (JC virus) / infections, hepatitis B / secondary autoimmunity.
Neurology: Anatomy, Physiology and Pharmacology - Ocrelizumab (IV every 6 months, or subcutaneous).
Neurology: Multiple Sclerosis and inflammatory disease - Ocrelizumab is also licensed for early active primary progressive MS .
Neurology: Multiple Sclerosis and inflammatory disease - Ocrelizumab - early, active primary progressive MS.
Neurology: Multiple Sclerosis and inflammatory disease - Anti-CD20 (rituximab, ocrelizumab) | Hypogammaglobulinaemia , HBV reactivation , PCP, PML, severe COVID-19 (poor vaccine response)
Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination - Uses - B-cell lymphoma and CLL, RA, ANCA vasculitis, SLE (off-label), membranous nephropathy, MS (ocrelizumab, ofatumumab), myasthenia (MuSK), ITP, autoimmune haemolysis, pemphigus, cryoglobulinaemia, IgG4-RD.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (2 mentions)
- Neurology: Multiple Sclerosis and inflammatory disease (4 mentions)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)